Therefore, small molecules capable of blocking ST2-IL-33 interactions may produce similar therapeutic effects to mitigate GVHD development, and specific drug studies for diseases where sST2 is a biomarker can be conducted. The gene discussed is IL1RL1; the disease is graft versus host disease.